HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

seryl- leucyl- isoleucyl- glycyl- - arginyl- leucinamide

a proteinase-activated receptor-2-activating peptide; SL-NH2 is NOT Ser-Leu-NH2 here

Also Known As:

PAR-2 activation peptide; SL-NH2; SLIGRL-NH2

Networked: 16 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide: 16

Experts

1.	Kawabata, Atsufumi: 3 articles (07/2006 - 06/2002)
2.	Kawao, Naoyuki: 2 articles (07/2006 - 06/2002)
3.	Masuko, Takashi: 2 articles (07/2006 - 09/2003)
4.	Kuroda, Ryotaro: 2 articles (09/2003 - 06/2002)
5.	Katagiri, Norika: 1 article (01/2021)
6.	Kawana, Hiromasa: 1 article (01/2021)
7.	Kido, Kanta: 1 article (01/2021)
8.	Masaki, Eiji: 1 article (01/2021)
9.	Sugino, Shigekazu: 1 article (01/2021)
10.	Yamauchi, Masanori: 1 article (01/2021)

Related Diseases

1.	Pancreatitis 02/01/2005 - "We found that experimental acute pancreatitis is more severe in PAR-2(-/-) than in wild-type mice and that in vivo activation of PAR-2, achieved by parenteral administration of the PAR-2-activating peptide SLIGRL-NH2, reduces the severity of pancreatitis. "
2.	Bacillary Dysentery (Shigellosis) 08/09/2010 - "The aim of this study was to determine changes of PAR-2 expression in distal colon and the sensitivity of colonic muscle to SLIGRL-NH2, the PAR-2-activating peptide (PAR-2-AP) following bacillary dysentery. "
3.	Hyperalgesia 01/22/2021 - "Intraplantar injection of SLIGRL-NH2 elicited spontaneous nociceptive behavior and hyperalgesia. " 10/01/2006 - "Mechanical and thermal hyperalgesia induced by SLIGRL-NH2 were inhibited by mS100A9p. " 03/26/2001 - "The PAR-2-activating peptide SLIGRL-NH2 administered by the intraplantar (i.pl.) route, produced thermal, but not mechanical, hyperalgesia in the rat, although the PAR-2-inactive control peptide LSIGRL-NH2 had no effect. " 06/01/2002 - "The thermal hyperalgesia following an intraplantar (i.pl.) administration of the PAR-2-activating peptide SLIGRL-NH2 was completely abolished by the capsaicin receptor antagonist capsazepine. "
4.	Pruritus (Itching) 11/01/2016 - "Co-injection of SLIGRL-NH2 (40nmol) with either the slow-release H2S donor GYY4137 (1 and 3nmol) or the spontaneous donor NaHS (1 and 0.3nmol) significantly reduced pruritus. " 09/26/2014 - "In addition to reducing trypsin-evoked itching, MVIIA or Phα1β also prevented the itching elicited by intradermal (i.d.) injection of SLIGRL-NH2, compound 48/80 or chloroquine, although they did not affect H2O2-induced scratching behavior. " 01/14/2014 - "Acute pruritus was induced in ICR mice by a single intradermal injection of histamine, 4-methylhistamine, serotonin, compound 48/80, substance P (SP), or the proteinase-activated receptor-2 (PAR-2)-activating peptide SLIGRL-NH2. "
5.	Inflammation (Inflammations) 04/01/2002 - "Intracolonic injection of SLIGRL-NH2 elevated spinal Fos expression and caused increased intestinal permeability but did not cause detectable inflammation. " 03/01/2005 - "Proteinase-activated receptor 2 activating peptide SLIGRL-NH2 (PAR-2 activating peptide [ap]) or control peptide LSIGRL-NH2 (PAR-2 control peptide [cp]) was administered alone or in conjunction with ovalbumin intranasally to mice, and AHR and airway inflammation were evaluated. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Trypsin
3.	PAR-2 Receptor
4.	p-Methoxy-N-methylphenethylamine
5.	TRPV Cation Channels
6.	Therapeutic Uses
7.	Neurotransmitter Agents (Neurotransmitter)
8.	Substance P
9.	Serotonin (5 Hydroxytryptamine)
10.	Peptide Hydrolases (Proteases)

Related Therapies and Procedures

1.	Intradermal Injections